Logo image of CALT

Calliditas Therapeutics AB (CALT) Stock Fundamental Analysis

NASDAQ:CALT - Nasdaq - US13124Q1067 - ADR - Currency: USD

40.0001  -0.16 (-0.4%)

Fundamental Rating

3

Taking everything into account, CALT scores 3 out of 10 in our fundamental rating. CALT was compared to 194 industry peers in the Pharmaceuticals industry. CALT may be in some trouble as it scores bad on both profitability and health. CALT is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CALT had negative earnings in the past year.
In the past year CALT has reported a negative cash flow from operations.
In the past 5 years CALT always reported negative net income.
In the past 5 years CALT always reported negative operating cash flow.
CALT Yearly Net Income VS EBIT VS OCF VS FCFCALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

CALT has a Return On Assets (-27.49%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -449.82%, CALT is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -27.49%
ROE -449.82%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
CALT Yearly ROA, ROE, ROICCALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

CALT has a Gross Margin of 93.46%. This is amongst the best in the industry. CALT outperforms 96.41% of its industry peers.
The Profit Margin and Operating Margin are not available for CALT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALT Yearly Profit, Operating, Gross MarginsCALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

CALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CALT has about the same amount of shares outstanding.
The number of shares outstanding for CALT has been increased compared to 5 years ago.
Compared to 1 year ago, CALT has a worse debt to assets ratio.
CALT Yearly Shares OutstandingCALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CALT Yearly Total Debt VS Total AssetsCALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

A Debt/Equity ratio of 9.44 is on the high side and indicates that CALT has dependencies on debt financing.
CALT has a Debt to Equity ratio of 9.44. This is amonst the worse of the industry: CALT underperforms 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.44
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.73%
CALT Yearly LT Debt VS Equity VS FCFCALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 2.69 indicates that CALT has no problem at all paying its short term obligations.
CALT has a Current ratio of 2.69. This is comparable to the rest of the industry: CALT outperforms 44.62% of its industry peers.
CALT has a Quick Ratio of 2.59. This indicates that CALT is financially healthy and has no problem in meeting its short term obligations.
CALT has a Quick ratio (2.59) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.59
CALT Yearly Current Assets VS Current LiabilitesCALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for CALT have decreased strongly by -64.52% in the last year.
The Revenue has grown by 39.27% in the past year. This is a very strong growth!
Measured over the past years, CALT shows a very strong growth in Revenue. The Revenue has been growing by 1013.57% on average per year.
EPS 1Y (TTM)-64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.54%
Revenue 1Y (TTM)39.27%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Sales Q2Q%107.8%

3.2 Future

Based on estimates for the next years, CALT will show a very strong growth in Earnings Per Share. The EPS will grow by 78.56% on average per year.
CALT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.98% yearly.
EPS Next Y127%
EPS Next 2Y105.23%
EPS Next 3Y87.75%
EPS Next 5Y78.56%
Revenue Next Year70.05%
Revenue Next 2Y66.46%
Revenue Next 3Y58.16%
Revenue Next 5Y39.98%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CALT Yearly Revenue VS EstimatesCALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
CALT Yearly EPS VS EstimatesCALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100 150 200 250

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CALT. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 10.59, which indicates a very decent valuation of CALT.
CALT's Price/Forward Earnings ratio is rather cheap when compared to the industry. CALT is cheaper than 87.69% of the companies in the same industry.
CALT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.71.
Industry RankSector Rank
PE N/A
Fwd PE 10.59
CALT Price Earnings VS Forward Price EarningsCALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALT Per share dataCALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

CALT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CALT's earnings are expected to grow with 87.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y105.23%
EPS Next 3Y87.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CALT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Calliditas Therapeutics AB

NASDAQ:CALT (9/20/2024, 8:00:02 PM)

40.0001

-0.16 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners0.08%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.08B
Analysts81.54
Price Target45.37 (13.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-176.69%
Min EPS beat(2)-181.66%
Max EPS beat(2)-171.73%
EPS beat(4)1
Avg EPS beat(4)-312.91%
Min EPS beat(4)-979.13%
Max EPS beat(4)80.89%
EPS beat(8)4
Avg EPS beat(8)-142.18%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.01%
Min Revenue beat(2)-22.04%
Max Revenue beat(2)22.03%
Revenue beat(4)2
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-22.04%
Max Revenue beat(4)23.96%
Revenue beat(8)4
Avg Revenue beat(8)20.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.89%
PT rev (3m)6.52%
EPS NQ rev (1m)-0.67%
EPS NQ rev (3m)61.18%
EPS NY rev (1m)-0.67%
EPS NY rev (3m)-20.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.59
P/S 6.82
P/FCF N/A
P/OCF N/A
P/B 102.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)3.78
Fwd EY9.44%
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS5.87
BVpS0.39
TBVpS-1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.49%
ROE -449.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.46%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 9.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.59
Altman-Z N/A
F-Score2
WACC6.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.54%
EPS Next Y127%
EPS Next 2Y105.23%
EPS Next 3Y87.75%
EPS Next 5Y78.56%
Revenue 1Y (TTM)39.27%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Sales Q2Q%107.8%
Revenue Next Year70.05%
Revenue Next 2Y66.46%
Revenue Next 3Y58.16%
Revenue Next 5Y39.98%
EBIT growth 1Y-36.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.93%
EBIT Next 3Y83.96%
EBIT Next 5Y69.01%
FCF growth 1Y59.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.92%
OCF growth 3YN/A
OCF growth 5YN/A